Multicenter Pheochromocytoma and Paraganglioma Evaluation

Launched by FELIX BEUSCHLEIN · Nov 10, 2017

Keywords

ClinConnect Summary

This clinical trial is studying how different follow-up care options can help patients with pheochromocytomas and paragangliomas (PPGL), which are types of tumors that can affect hormone levels and blood pressure. The trial is open to anyone aged 5 and older who has been newly diagnosed with PPGL, has a history of these tumors, or carries genetic mutations that increase their risk for developing PPGL.

Participants in the study will be randomly assigned to one of two groups. One group will receive standard follow-up care, where they will be reminded to schedule annual check-ups but won’t receive active reminders. The other group will receive special follow-up care, which includes regular reminders to help them keep their appointments. This trial is currently recruiting participants, and all individuals will need to give informed consent before joining. It's important to note that while pregnant women can participate, certain tests will be limited during pregnancy.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • male and female patients (≥ 5 years of age), who fulfill one or more of the following criteria: (i) Patients with a newly diagnosed PPGL. (ii) Patients with a previous history of PPGLs. (iii) Carrier of genetic mutations known to predispose for the development of PPGLs.
• • All subjects must have read, understood and signed the informed consent form, before inclusion into the study protocol. Signed parental consent must be obtained for children with suspected PPGLs who are enrolled in the study.
• Exclusion Criteria:
• • Patients with impaired mental capacity that precludes informed consent.
• • Pregnancy does not constitute criteria for exclusion from the protocol. However, in pregnant women no Clonidine testing, no PET scanning, MIBG scanning or contrast CT will be performed.
• • Patients at risk from injury from the MRI magnet due to implantable metal or who suffer from anxiety in enclosed spaces are excluded from MRI.